@entity1140 treatment of graft-versus-host disease developing or exacerbating during prophylaxis and therapy with XXXX and/or other immunosuppressants. Japanese @entity1140 BMT Study Group.

@entity1 @entity8 @entity390 @entity391 @entity205 @entity4432 @entity1140
A phase II study of the efficacy and safety of @entity1140 , a new potent immunosuppressant, has been conducted in 49 @entity1 with GVHD after allogeneic BMT. Eighteen @entity1 with acute GVHD and 31 with chronic GVHD entered the study. @entity1140 was administered at an initial dose of 0.05 mg/kg i.v. or 0.15 mg/kg orally twice a day to those whose GVHD had become uncontrollable with @entity205 and/or other immunosuppressants. The response to @entity1140 was evaluated in 13 @entity1 with acute and 26 with chronic GVHD. A marked response was observed in 5 and a good response in 2 of 13 @entity1 with acute GVHD. For those with chronic GVHD, the response was marked in 2 @entity1 , good in 10 and poor in 8. The most common adverse effects were @entity8 (53.1%), followed by @entity390 and @entity391 (30.6%) and a feeding of warmth (18.4%). There was a correlation between @entity8 and whole blood levels of @entity1140 . The dose should be adjusted to keep a trough level between 15 and 25 ng/ml. @entity1140 is promising in the treatment of both @entity4432 , even if it is intractable with other immunosuppressants, and may be most effective if administered early in the course of GVHD.
